SUDEEPPHRMSudeep Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUDEEPPHRM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 26.7% YoY
- • Profit growth: 28.2% YoY
- • ROE: 19.6%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +14.1%
Bull case
- • Revenue growth: 26.7% YoY
- • Profit growth: 28.2% YoY
- • ROE: 19.6%
- • Price vs SMA200: above
Bear case
- • Valuation vs sector: P/E 60.9 vs sector 35.5
- • Dividend yield: 0.14%
- • RSI: 36
- • MACD: bearish
Key risks
- • Valuation vs sector: P/E 60.9 vs sector 35.5
- • Dividend yield: 0.14%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹57.08). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.